HCPCS Level II code J7185 denotes the provision of recombinant factor VIII (antihemophilic factor, Xyntha) measured per international unit. This code is central to billing for replacement therapy for patients with hemophilia A and other factor VIII deficiencies and is widely used across hospital outpatient departments, infusion centers, and physician offices. Nationally, accurate coding of high-cost biologic clotting factors affects payer coverage, prior authorization workflows, and cost management for specialty drug programs.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for factor VIII replacement, typical sites of service, and common billing considerations tied to per-unit dosing. The publication outlines benchmarks and reimbursement patterns where available, highlights relevant policy updates affecting coverage and prior authorization, and summarizes operational implications for billing teams and infusion providers.

This summary is intended to inform revenue cycle, pharmacy, and clinical leadership about the billing identity and operational use of J7185, and what to expect when managing claims for recombinant factor VIII therapy.